LEAMINGTON, Ontario, March 17, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced that its medical cannabis division, Tilray Medical, has expanded its medical cannabis offering and launched the first EU GMP medical cannabis oil products in Malta. Tilray’s EU-GMP medical cannabis products are now available in pharmacies across Malta, providing patients with safe and reliable access to high-quality medical cannabis.
Denise Faltischek, Tilray’s Chief Strategy Officer and Head of International Business, said, “Demand for medical cannabis in Malta is growing rapidly and we are incredibly proud to service patients with the high-quality medical cannabis products they rely on and in the formats they prefer.”
In Malta, patients may obtain prescriptions for medical cannabis and a medical cannabis card through family doctors. Medical cannabis cards are issued by Malta’s Superintendent of Public Health.
Tilray has a pioneering track record as a company committed to making EU GMP-certified, pharmaceutical-grade medical cannabis products available to patients in need around the world and was the first to successfully export medical cannabis from North America and import medical cannabis products into the E.U. in 2016.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, and Symbios. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents.
This content is published on behalf of the above source. Please contact them directly for any concern related to the above.